Coverdale Shirley A, Samarasinghe Dev A, Lin Rita, Kench James, Byth Karen, Khan Mahbub H, Crewe Evelyn, Liddle Christopher, George Jacob, Farrell Geoffrey C
The Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, NSW, Australia.
Am J Gastroenterol. 2003 Jun;98(6):1384-90. doi: 10.1111/j.1572-0241.2003.07468.x.
We tested whether fibrotic progression in chronic hepatitis C could be predicted by liver tests, antipyrine clearance, or platelet count.
In 58 patients (6 untreated, 52 interferon-treated), a second liver biopsy was taken median 4.5 yr after first histologic diagnosis. We used receiver operating characteristic curves to determine whether changes in conventional liver tests, antipyrine clearance, or platelet count were predictive of altered hepatic fibrosis score.
Apart from a weak association with change in ALT, conventional liver tests (albumin, bilirubin, prothrombin time) failed to correlate with changes (Delta) in hepatic fibrosis, but there were significant correlations between deltaantipyrine clearance or deltaplatelet count and deltafibrosis score (p < 0.01). As indicated by areas under the receiver operating characteristic curves, the diagnostic accuracy of deltaantipyrine clearance for fibrotic progression was 68%; for Deltaplatelet count it was 80%. With defined cut-off values (-0.05 ml/min/kg for deltaantipyrine clearance; -41 x 10(9)/L for deltaplatelet count), the negative predictive values for fibrotic progression were 85% with antipyrine clearance and 89% with platelet count. Corresponding positive predictive values were 48% and 91%, respectively.
Changes in antipyrine clearance and platelet count are more sensitive than conventional tests for indicating fibrotic change in chronic hepatitis C. Both could be used to reliably identify those who do not have fibrotic progression, and platelet count also has a high positive predictive value for disease progression.
我们检测了慢性丙型肝炎的纤维化进展能否通过肝功能检查、安替比林清除率或血小板计数来预测。
58例患者(6例未治疗,52例接受干扰素治疗)在首次组织学诊断后中位4.5年时进行了第二次肝活检。我们使用受试者工作特征曲线来确定传统肝功能检查、安替比林清除率或血小板计数的变化是否可预测肝纤维化评分的改变。
除了与ALT变化有微弱关联外,传统肝功能检查(白蛋白、胆红素、凝血酶原时间)与肝纤维化的变化(Delta)无相关性,但安替比林清除率变化或血小板计数变化与纤维化评分变化之间存在显著相关性(p<0.01)。如受试者工作特征曲线下面积所示,安替比林清除率变化对纤维化进展的诊断准确性为68%;血小板计数变化为80%。设定临界值(安替比林清除率变化为-0.05 ml/min/kg;血小板计数变化为-41×10⁹/L)时,安替比林清除率对纤维化进展的阴性预测值为85%,血小板计数为89%。相应的阳性预测值分别为48%和91%。
安替比林清除率和血小板计数的变化在指示慢性丙型肝炎纤维化变化方面比传统检查更敏感。两者均可用于可靠地识别无纤维化进展的患者,并且血小板计数对疾病进展也具有较高的阳性预测值。